Q1 Earnings Forecast for Liquidia Issued By HC Wainwright

Liquidia Co. (NASDAQ:LQDA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Liquidia in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.49) per share for the quarter. HC Wainwright has a "Buy" rating and a $29.00 price target on the stock. The consensus estimate for Liquidia's current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia's FY2025 earnings at ($1.53) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.47) EPS and FY2028 earnings at ($0.07) EPS.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). The company had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%.

LQDA has been the subject of a number of other reports. Wells Fargo & Company began coverage on Liquidia in a research note on Friday, December 20th. They issued an "overweight" rating and a $20.00 price target for the company. Scotiabank increased their price objective on shares of Liquidia from $30.00 to $34.00 and gave the company a "sector outperform" rating in a research report on Thursday, March 20th. Finally, Needham & Company LLC boosted their target price on shares of Liquidia from $19.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $26.63.

Remove Ads

Liquidia Trading Down 0.5 %

Shares of LQDA stock traded down $0.08 during trading hours on Monday, reaching $15.59. 204,811 shares of the company's stock were exchanged, compared to its average volume of 896,365. Liquidia has a fifty-two week low of $8.26 and a fifty-two week high of $16.81. The stock's 50 day moving average is $14.87 and its 200-day moving average is $12.27. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -9.56 and a beta of 0.07.

Insider Activity at Liquidia

In related news, CFO Michael Kaseta sold 23,370 shares of the stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $275,298.60. Following the completion of the transaction, the chief financial officer now directly owns 401,755 shares of the company's stock, valued at approximately $4,732,673.90. This represents a 5.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Russell Schundler sold 16,393 shares of the firm's stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $193,109.54. Following the completion of the transaction, the general counsel now directly owns 573,478 shares in the company, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,245 shares of company stock worth $843,326. 30.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LQDA. Corebridge Financial Inc. boosted its position in shares of Liquidia by 2.3% during the 4th quarter. Corebridge Financial Inc. now owns 31,516 shares of the company's stock valued at $371,000 after acquiring an additional 694 shares during the last quarter. Catalina Capital Group LLC lifted its holdings in Liquidia by 6.5% in the fourth quarter. Catalina Capital Group LLC now owns 18,307 shares of the company's stock valued at $215,000 after acquiring an additional 1,125 shares during the last quarter. Cetera Investment Advisers grew its position in Liquidia by 4.3% in the fourth quarter. Cetera Investment Advisers now owns 31,243 shares of the company's stock worth $367,000 after acquiring an additional 1,277 shares during the period. Summit Investment Advisors Inc. increased its stake in Liquidia by 35.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after acquiring an additional 1,719 shares during the last quarter. Finally, Sigma Planning Corp raised its position in Liquidia by 3.4% in the fourth quarter. Sigma Planning Corp now owns 65,210 shares of the company's stock valued at $767,000 after purchasing an additional 2,115 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).